UCLA trial shows cancer vaccine elicits strong immune response

A recent study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has revealed promising results for a novel cancer vaccine, ELI-002 2P, designed to target the KRAS mutation, one of the most common drivers of cancer. The findings demonstrate that the vaccine can elicit strong and durable immune responses in patients suffering from pancreatic and colorectal cancer, two of the most challenging malignancies to treat. In the study with 25 participants, the median relapse-free survival was recorded at 16.33 months, while the median overall survival reached 28.94 months, both surpassing historical averages. This advancement in immunotherapy could potentially lead to improved outcomes for patients with KRAS-driven cancers, particularly given the high recurrence rates following standard treatments.

The historical context of this breakthrough lies in the challenges of treating cancers driven by KRAS mutations, prevalent in approximately 25% of solid tumors and contributing to about 90% of pancreatic cancers and 50% of colorectal cancers. ELI-002 2P is designed as an off-the-shelf vaccine, meaning it does not require the complex and time-consuming customization often needed for personalized cancer therapies. Instead, this standardized product aims to broadly stimulate the immune system, enabling it to recognize and attack cancer cells driven by KRAS mutations. The study shows that this innovative approach to immunotherapy could help bridge the gap between personalized medicine and more accessible treatment options for a wider range of patients.

The implementation of this trial involved administering ELI-002 2P to 25 patients who had previously undergone surgery for pancreatic ductal adenocarcinoma or colorectal cancer and exhibited minimal residual disease. Through a series of injections, the vaccine utilizes specialized amphiphile technology developed by Elicio Therapeutics, which directs antigens to the lymph nodes where immune responses can be effectively activated. Remarkably, 84% of participants developed KRAS-specific T cells, including both CD4+ helper and CD8+ killer cells. Many of these T cells persisted over time, suggesting a long-lasting immune response that could be vital for preventing cancer recurrence.

The broader implications of this study extend beyond individual patient outcomes. The vaccine's ability to generate strong immune responses has the potential to reduce healthcare costs associated with recurrent cancers and improve overall survival rates. Additionally, the study's findings could pave the way for further research into other cancer-driving mutations, enhancing the understanding of immune response mechanisms in oncology. With 67% of tested patients also developing responses to additional tumor-associated mutations, ELI-002 2P represents a significant step toward broader anti-tumor activity and more effective cancer therapies.

Looking ahead, the research team has completed enrollment for a larger Phase 2 study of ELI-002 7P, a next-generation version of the vaccine that aims to target a broader range of KRAS mutations. This ongoing research signifies a commitment to advancing cancer immunotherapy and enhancing treatment options for patients with KRAS-driven cancers. As the understanding of immune responses in oncology continues to evolve, the success of ELI-002 2P could have lasting ramifications for future cancer therapies and patient care.